Rapamycin resistance is linked to defective regulation of Skp2

Hana Totary-Jain, Despina Sanoudou, Cula N. Dautriche, Hillary Schneller, Lester Zambrana, Andrew R. Marks

Research output: Contribution to journalArticle

28 Citations (Scopus)


The mammalian target of rapamycin (mTOR) plays a role in controlling malignant cellular growth. mTOR inhibitors, including rapamycin (sirolimus), are currently being evaluated in cancer trials. However, a significant number of tumors are rapamycin resistant. In this study, we report that the ability of rapamycin to downregulate Skp2, a subunit of the ubiquitin protein ligase complex, identifies tumors that are sensitive to rapamycin. RNA interference (RNAi)-mediated silencing of Skp2 in human tumor cells increased their sensitivity to rapamycin in vitro and inhibited the growth of tumor xenografts in vivo. Our findings suggest that Skp2 levels are a key determinant of antitumor responses to mTOR inhibitors, highlighting a potentially important pharmacogenomic marker to predict sensitivity to rapamycin as well as Skp2 silencing strategies for therapeutic purposes.

Original languageEnglish
Pages (from-to)1836-1843
Number of pages8
JournalCancer Research
Issue number7
Publication statusPublished - 1 Apr 2012
Externally publishedYes


ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Totary-Jain, H., Sanoudou, D., Dautriche, C. N., Schneller, H., Zambrana, L., & Marks, A. R. (2012). Rapamycin resistance is linked to defective regulation of Skp2. Cancer Research, 72(7), 1836-1843. https://doi.org/10.1158/0008-5472.CAN-11-2195